Biotest AG: Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement
Biotest AG / Key word(s): Contract / Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement - Manufacturing & Supply agreement - License agreement for ADMA's Respiratory Syncytial Virus IGIV product candidate for EU and selected countries
Under the terms of the agreement, ADMA has agreed to purchase exclusively from BPC its worldwide requirements and product supply of RSV (Respiratory Syncytial Virus) immune globulin (RI-002) manufactured from human plasma containing RSV antibodies. The initial term of the agreement is for ten years. RI-002 is a specialty immune globulin for primary immune deficiency patients, which is derived from human plasma containing high levels of Respiratory Syncytial Virus (RSV) antibodies. For patients that are immunocompromised naturally or medically due to an underlying illness or a transplant, an RSV infection can present significant morbidity and mortality. ADMA is currently preparing a pivotal Phase III clinical trial in primary immune deficiency patients with this product in the United States. Also in connection with the manufacturing and supply agreement, ADMA has out-licensed RI-002 to Biotest AG, to market and sell in Europe and selected countries in North Africa and the Middle East. In return for this license, Biotest AG will compensate ADMA upon the completion of certain milestones as well as pay a royalty based on a percentage of sales of RSV immune globulin in the territory. 'This specialty immune globulin product will perfectly complement our hyper-immune globulin portfolio', Prof. Gregor Schulz, CEO of Biotest comments this deal. About ADMA's lead product candidate About ADMA Biologics, Inc. Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 End of Corporate News 16.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.medientreff.de and www.dgap.de |
Language: | English | |
Company: | Biotest AG | |
Landsteinerstraße 5 | ||
63303 Dreieich | ||
Germany | ||
Phone: | 0 61 03 - 8 01-0 | |
Fax: | 0 61 03 - 8 01-150 | |
E-mail: | investor_relations@biotest.de | |
Internet: | http://www.biotest.de | |
ISIN: | DE0005227235, DE0005227201 | |
WKN: | 522723, 522720 | |
Indices: | SDAX | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart | |
End of News | DGAP News-Service |
199187 16.01.2013 |